|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:SUCLA2-CTTNBP2NL (FusionGDB2 ID:87336) |
Fusion Gene Summary for SUCLA2-CTTNBP2NL |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: SUCLA2-CTTNBP2NL | Fusion gene ID: 87336 | Hgene | Tgene | Gene symbol | SUCLA2 | CTTNBP2NL | Gene ID | 8803 | 55917 |
| Gene name | succinate-CoA ligase ADP-forming subunit beta | CTTNBP2 N-terminal like | |
| Synonyms | A-BETA|A-SCS|LINC00444|MTDPS5|SCS-betaA | - | |
| Cytomap | 13q14.2 | 1p13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialATP-specific succinyl-CoA synthetase subunit betaATP-specific succinyl-CoA synthetase, beta subunitlong intergenic non-protein coding RNA 444mitochondrial succinyl-CoA ligase [ADP-forming] | CTTNBP2 N-terminal-like protein | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | Q9P2B4 | |
| Ensembl transtripts involved in fusion gene | ENST00000378654, ENST00000544100, ENST00000534875, ENST00000543413, ENST00000497202, | ENST00000271277, ENST00000607039, | |
| Fusion gene scores | * DoF score | 7 X 7 X 4=196 | 6 X 5 X 3=90 |
| # samples | 7 | 6 | |
| ** MAII score | log2(7/196*10)=-1.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/90*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: SUCLA2 [Title/Abstract] AND CTTNBP2NL [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CTTNBP2NL(112958886)-SUCLA2(48571158), # samples:2 CTTNBP2NL(112958886)-SUCLA2(48589384), # samples:2 SUCLA2(48575316)-CTTNBP2NL(112991564), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene breakpoints across SUCLA2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CTTNBP2NL (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | OV | TCGA-10-0928-01A | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| ChimerDB4 | OV | TCGA-10-0928-01A | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
Top |
Fusion Gene ORF analysis for SUCLA2-CTTNBP2NL |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000378654 | ENST00000271277 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| 5CDS-intron | ENST00000378654 | ENST00000607039 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| 5UTR-3CDS | ENST00000544100 | ENST00000271277 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| 5UTR-intron | ENST00000544100 | ENST00000607039 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| intron-3CDS | ENST00000534875 | ENST00000271277 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| intron-intron | ENST00000534875 | ENST00000607039 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| intron-3CDS | ENST00000543413 | ENST00000271277 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| intron-intron | ENST00000543413 | ENST00000607039 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| 5UTR-3CDS | ENST00000497202 | ENST00000271277 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| 5UTR-intron | ENST00000497202 | ENST00000607039 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000378654 | SUCLA2 | chr13 | 48575316 | - | ENST00000271277 | CTTNBP2NL | chr1 | 112991564 | + | 5720 | 147 | 57 | 1967 | 636 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000378654 | ENST00000271277 | SUCLA2 | chr13 | 48575316 | - | CTTNBP2NL | chr1 | 112991564 | + | 0.001031264 | 0.9989687 |
Top |
Fusion Genomic Features for SUCLA2-CTTNBP2NL |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| SUCLA2 | chr13 | 48575315 | - | CTTNBP2NL | chr1 | 112991563 | + | 5.23E-10 | 1 |
| SUCLA2 | chr13 | 48575315 | - | CTTNBP2NL | chr1 | 112991563 | + | 5.23E-10 | 1 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for SUCLA2-CTTNBP2NL |
| Go to FGviewer for the breakpoints of chr13:48575316-chr1:112991564 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | CTTNBP2NL |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Regulates lamellipodial actin dynamics in a CTTN-dependent manner. {ECO:0000250|UniProtKB:Q8SX68}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | CTTNBP2NL | chr13:48575316 | chr1:112991564 | ENST00000271277 | 2 | 6 | 87_285 | 33.0 | 640.0 | Coiled coil | Ontology_term=ECO:0000255 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | SUCLA2 | chr13:48575316 | chr1:112991564 | ENST00000378654 | - | 1 | 11 | 61_288 | 30.0 | 464.0 | Domain | ATP-grasp |
| Hgene | SUCLA2 | chr13:48575316 | chr1:112991564 | ENST00000378654 | - | 1 | 11 | 105_107 | 30.0 | 464.0 | Nucleotide binding | ATP |
| Hgene | SUCLA2 | chr13:48575316 | chr1:112991564 | ENST00000378654 | - | 1 | 11 | 380_382 | 30.0 | 464.0 | Region | Substrate binding%3B shared with subunit alpha |
Top |
Fusion Gene Sequence for SUCLA2-CTTNBP2NL |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000378654_ENST00000271277_TCGA-10-0928-01A_SUCLA2_chr13_48575316_-_CTTNBP2NL_chr1_112991564_length(transcript)=5720nt_BP=147nt CCGCCTGTCGCCTGTGCGCCTGCGCGCGGCGCCGAGGGGACGGGGTCCGACTCAGAAATGGCGGCCTCCATGTTCTACGGCAGGCTAGTG GCCGTGGCCACCCTTCGGAACCACCGGCCTCGGACGGCCCAGCGGGCTGCTGCTCAGGCCCAACACAGAGATACTTTCATTGAAGAACGC TATGGAAAATATAACATCAGTGATCCTTTAATGGCTCTACAGAGAGATTTTGAAACACTGAAGGAGAAAAATGATGGCGAAAAGCAGCCA GTCTGCACAAATCCACTCTCTATTCTTAAGGTTGTGATGAAGCAGTGCAAGAACATGCAGGAGCGCATGCTGTCCCAGCTGGCTGCTGCT GAGAGCAGGCACCGAAAGGTGATCCTAGACCTTGAGGAAGAAAGGCAGCGGCATGCACAGGATACGGCTGAAGGAGATGATGTCACCTAC ATGCTAGAGAAGGAAAGAGAGAGGCTGACTCAACAGTTGGAATTTGAAAAATCCCAAGTGAAAAAGTTTGAAAAAGAACAGAAGAAGCTC TCTAGTCAGCTGGAAGAGGAGCGCTCCCGCCACAAGCAGCTCTCATCCATGCTAGTGCTTGAGTGCAAGAAAGCCACCAACAAGGCAGCC GAGGAAGGACAGAAGGCAGGAGAGCTGAGCCTGAAATTGGAGAAGGAGAAGAGCCGGGTGAGTAAACTGGAAGAAGAGTTGGCAGCTGAG AGAAAGAGAGGCTTGCAGACTGAGGCCCAGGTAGAGAAGCAGTTATCAGAGTTTGACATCGAAAGGGAACAACTGAGAGCAAAACTGAAC CGAGAAGAGAACCGGACCAAAACCCTGAAAGAAGAAATGGAAAGTTTAAAGAAGATAGTGAAGGACCTAGAGGCTTCCCACCAGCACAGT AGCCCTAATGAGCAATTGAAGAAACCAGTAACCGTGTCCAAAGGCACAGCAACTGAGCCTCTCATGCTAATGTCTGTGTTTTGCCAAACA GAGAGTTTTCCAGCAGAAAGAACCCATGGGAGCAACATAGCCAAGATGACAAACACTGGGCTGCCTGGTCCTGCCACTCCTGCTTACTCA TATGCAAAAACCAATGGCCATTGTGACCCAGAGATACAAACTACCAGGGAGCTGACTGCAGGCAACAATGTAGAAAACCAGGTGCCTCCA CGGGAAAAATCTGTGGCATTGGCCCAAGAGAAACCAGTGGAGAATGGTGGGTGTCCTGTGGGGATTGAGACTCCAGTCCCAATGCCCAGT CCCCTCTCTTCCAGTGGGAGCTCACTGTCTCCCAGCAGCACTGCCTCCTCCTCTCTAACATCCTCTCCTTGCTCTTCGCCGGTACTCACT AAGCGTTTATTGGGGTCATCAGCTAGCAGCCCTGGCTACCAGTCATCGTACCAAGTAGGGATCAACCAACGGTTCCATGCAGCTCGCCAC AAATTTCAGTCCCAAGCAGATCAGGACCAACAAGCCAGTGGCCTACAGAGCCCTCCATCCAGGGATTTATCCCCCACCCTCATAGACAAC TCTGCCGCCAAGCAGCTGGCCCGAAACACAGTCACTCAGGTGCTCTCCAGATTCACTAGCCAACAAGGGCCAATCAAGCCAGTCTCTCCC AACAGCTCTCCCTTTGGCACAGACTATCGAAATCTAGCCAACACTGCCAATCCAAGAGGTGACACAAGCCATTCACCTACTCCAGGGAAA GTGTCCAGTCCCCTGAGCCCCCTGTCTCCAGGAATCAAGTCCCCAACCATCCCCAGAGCTGAGAGAGGAAACCCTCCACCCATCCCACCC AAGAAACCTGGCCTCACCCCTTCTCCATCTGCTACCACTCCATTGACCAAAACTCATTCCCAGGCAGCCTCTTTGACCACTGCAGAAGAC CTTGCCAGCAGCTGCTCTTCCAATACTGTTGTAGCAAATGGTAAGGATGTTGAGTTACTTTTGCCTACCAGCAGCTAGTCCCTAGGAGGG AGTCTCCACGTTTGACATTCCATCAGATTTCGTCCAAAAGCTCAGTCAGACTTCTGAGTCAGATTATGTTATTTATTTTGATAGTAGCTG AAACCATCTGTATAATACATTTAGTATATTTCACCATTTTGTATTTTTTTAAGTAGAAACTGAGTAGTTTGGATTTTTATGGCTCACATC TTTTTACTGAAGCCAGAAAGGCACCTCAAAGATGTCTCAAGCTCAGCAGTCACCGTCATGTTGTGATGAAGAAAGCGAATCACCAGGTGG TGATTTGCTATCTATTTGAGAACTAGAATCACTCAACACTCATTTTGAATTATGCAGAAGTGGTTCATGCAGATTTTTATTCCAGATGAA CATGTTTTAAAAGTGCCTGAAATATGACTGCCATATGAATGTGATTCTGCAGCAAAAAACACAAAATAGATCATTTAATTACAGAAAATG AGATCCTCTGTGAATTCTGAATGTTAAAAACCAACACTGCTTTTAATCCTCTTTTAATGTTTTAATACAAGCTTTGTGTTCTGAAACAAG GCTGCATAAGTAGAATGGGAATCCTTCTAAAGGTGGGTGTGAACTCACCACAAGCTGAGCTTTATAGAGCCCTTGAGAAACCCTCCTGAG CACTAAGCAGTTGGGGTGCTGATTTTCTTGTACTTTTGAAAAATTAAGTCACTCCCAGTTTCCTGCATAAGTTCTTGAACAGAATGAAAT CACATCTCCATTCAAAAAATGTCTCAAGCATCTACTGTTGTGTAAGGAACTTCTGATTCTGATTGCTGTTACTTGAATAGGAAATGGTTA CTCATTCTGTATAAAAGTTTTGCAAGAGAATGAATTTTTTATTCTGTAATCAAAAAGCAATAACTTGAAATTCACTCTGTAATATTATAG GTCAGTCAGAATTATACAAGTTTTACCAAATTGTTACACTTATTCTCCAAGCTGCCAGAACCTGGTATCTGTATCTGTAAAACCAAATTA ACTTTTGCTTAAATGGGAAGTATACATATATCTGTATAGATACATTACCCCTTTACATGTTTAACATACACACACTTAAACACATAAATA CTAGTGTGATTATATCTTTGGAGTTTGCAATATAGCATAAAGGACAAGTAGAACTGCACATTAAGATTACCTACCGAAGCAACTAGATGT GGCTGGGACACAATCAAAGGAGGAATTTTGTCCACAGGAAGGTGAGGAAATTCCAAATGAAGCCTAGATCTTCAGTATCATAAAAAGGCA GAGCTGGCCAGGCACAGTGGCTCATGCCTGTAATCTTATCACTTTGGGAGGCTGAGATGGGAGGATCTCTTGAGACCAGGTGTTCAAGAC CAGCCTCATCAACATAGTGAGACCCCATCTCTATTAAAAAAATAAATAGGCAGAGCTAAACTAACCCCAGTGTCACAAAACTCAACTGGT CATATAAATGAGTGAAACAGGCCTCTCACACAAGCGATGTAAAACAGCTGGGAGCAGTGGGAGCTGTGGCAAACTAAAGTGCCCAAGCCG CATTTAAAAAGGGCATCTGTTCAGCTCCATCTGCTTGCTGCGGTGCAAGAATGCTAAACCAGGATTACCAGTTCTTCACATTTTTTGAAA TCCAAATTTTCATGAGAAACATTCTCATTTTTAAATATCAAGAAGTGATTTTAAAATGTTTAAATGGTGCTGGTTAAACAAACACGTCTG CAGCTGGATTTAGCTTGCAAGCTGCCAAGTTGCAACCTCTTTCATTCTAGAAACTTCTGTCATTTTCATCATAGCAAGTCTATGCGGACA AAAGCCTCCAAACTTTCCAACTGTGTAGGCCAGTACAGCTGGCAAGGTTCATAGAATATAATGGCTATCCCCCTCTGCCAAATAAGACTA TCCACAACCCAGCTCAGACACAGTGGTTATATGATTTTGTGTCCATACAGGAGAGGCCTTGGTGTCTTCACATACATTCTCTGAGCCAAC ATCTATCCAGCAGCCCTGACCTCCTGCTATAATTTAAGTCTATTTCCTTTTAATCTAATAAGAGTTGATAGTAAAAAGGCAGGTGATGGA AATCAGTGTATAAATCACAATGGAGTATATTGGCAACTCCACAGCTTATAGTTTGATAAAGGCAAATACATGAAAAATAAAAATGCTACT AATGCCCCAAGGTGTCTATCAAAATGATGTAGGGGGTATCTTAAACTGTCCAAGGCAATCATGCATTGAACTTTATTCCTATGCAGAGCC AAAACGAATAGTGTTGATAAAATAGCTAAACTTTCTAAACTGGAGAGGAGGCTACAGTGCCAGAGAGTTATTGTCTCTTTTGCTTTAAAT GGTAATCTTAAAAGTTGCATTGTGCTCTTCCTTTGTTTTGGGATAGATATATATAGAGAGAGATACTATAAGGAAGTTTATTTCTTAGGA AGTGCACTGAATAATGTATTTCTTTTACAGTGTAATATGGGGGTGGGGATATGCGAAAGAAATGTGTATTTTTGCTAGTTGCCTACCTTC TGAGATAAATAAGCACAATCTTGCAATGGATCCAATAACCCAGTTAGGTATTATAGATTAGTATTTAAGTTTGCTGTAGATTGTGTGTGT GTGTGCTAAGTAAAAGTTCCATGATTCACAATTTTAGTATTAACCCATGTTGCAAAAGCTGTTACTGGCCAACAGATTGTAATGATGTGT ACCATATAACACAAGCATTAACTAGGCATTAACGTTTGTAAAGCCAAATATACCATGCAGAAGTCTTCATTTTTATAGCAGACTGCATTA AAACAAGTTAAATCTTGCTGTTTGGGGGGAAATAGTCTTGTTTGTACAAAGTGAAAAATGGCACAATTTGGGCATATTTTGTTGGGAAGA GGGGGTGGTGTAGAGGGAGCACTTGACTGTGGCTTTGACAAAACAAATGAAGTCAATGACCCATCCAGGTTAGACTCCATAAGGAACTAA GACATTGATTTTCTTTAGAGTCTTAGAGCTGGAAAAAGCCTTTACAATAATCCAGTCTGTGATTTTTTAAACCTTTTGGTGGTTCTGGAC CTTTTTGAGAATCTTAGAAAAGCCATGGAGTTTATCCCTAGAAAAATGAATATGCCTATATGCAAAATTTGTTTGATGGCTTCATAGGAT CCAAAGACCCTGAAGCCATCCATGGCTCATGTATTTCTGCTTAAGAAAGCATAATCTTGTTCTGCTCTCTCATTTTACAAATGATTAATG CATCCCTTTTCAACTACTCCAGCGCTGTTGCTGCTGCAATGTTAGCAAATGCAAGCCAGAGAGAAGCACTTGAAAATCCTTTGATGTCTA AAAAATGTTCAAATAGTGTGGATGTTTACATATCTGAAGTTTTCAGCATTTAAGCAAATTAATGATCATTTCAACAAATACTAGCATATC CGGTTTCCCTTAATAGCCTGTCAGCAGTGCTGCCTTGTCAATTTGTGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGAATTCATAAGGAG TGCTTCTGATGCTTAGTCCTTGAAATGGAACTTCAACTGTCTTTCAAAACACTGGCTTCAAAATAGGATGTGTTTTCCTAATGAATCAGA AGTGGGCAATGAGCATTGTTCCACAGGAATAATTTTTAATTTAATTTCTATAAAACTAGTTGAGAAATGAGAGCCTGTCCACCCACCATT >In-frame_ENST00000378654_ENST00000271277_TCGA-10-0928-01A_SUCLA2_chr13_48575316_-_CTTNBP2NL_chr1_112991564_length(amino acids)=636AA_start in transcript=57_stop in transcript=1967 MAASMFYGRLVAVATLRNHRPRTAQRAAAQAQHRDTFIEERYGKYNISDPLMALQRDFETLKEKNDGEKQPVCTNPLSILKVVMKQCKNM QERMLSQLAAAESRHRKVILDLEEERQRHAQDTAEGDDVTYMLEKERERLTQQLEFEKSQVKKFEKEQKKLSSQLEEERSRHKQLSSMLV LECKKATNKAAEEGQKAGELSLKLEKEKSRVSKLEEELAAERKRGLQTEAQVEKQLSEFDIEREQLRAKLNREENRTKTLKEEMESLKKI VKDLEASHQHSSPNEQLKKPVTVSKGTATEPLMLMSVFCQTESFPAERTHGSNIAKMTNTGLPGPATPAYSYAKTNGHCDPEIQTTRELT AGNNVENQVPPREKSVALAQEKPVENGGCPVGIETPVPMPSPLSSSGSSLSPSSTASSSLTSSPCSSPVLTKRLLGSSASSPGYQSSYQV GINQRFHAARHKFQSQADQDQQASGLQSPPSRDLSPTLIDNSAAKQLARNTVTQVLSRFTSQQGPIKPVSPNSSPFGTDYRNLANTANPR GDTSHSPTPGKVSSPLSPLSPGIKSPTIPRAERGNPPPIPPKKPGLTPSPSATTPLTKTHSQAASLTTAEDLASSCSSNTVVANGKDVEL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for SUCLA2-CTTNBP2NL |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for SUCLA2-CTTNBP2NL |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for SUCLA2-CTTNBP2NL |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | SUCLA2 | C0023264 | Leigh Disease | 13 | CLINGEN |
| Hgene | SUCLA2 | C1838951 | LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX I DEFICIENCY | 13 | CLINGEN |
| Hgene | SUCLA2 | C1850597 | Leigh Syndrome Due To Mitochondrial Complex II Deficiency | 13 | CLINGEN |
| Hgene | SUCLA2 | C1850598 | Leigh Syndrome due to Mitochondrial Complex III Deficiency | 13 | CLINGEN |
| Hgene | SUCLA2 | C1850599 | Leigh Syndrome due to Mitochondrial Complex IV Deficiency | 13 | CLINGEN |
| Hgene | SUCLA2 | C1850600 | Leigh Syndrome due to Mitochondrial Complex V Deficiency | 13 | CLINGEN |
| Hgene | SUCLA2 | C2931891 | Necrotizing encephalopathy, infantile subacute, of Leigh | 13 | CLINGEN |
| Hgene | SUCLA2 | C2749864 | MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA) | 7 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Hgene | SUCLA2 | C0028754 | Obesity | 1 | CTD_human |
| Tgene | CTTNBP2NL | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies